For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||
![]() Philip Morris International IncPM US · Consumer Staples · USD Current price$192.73as of Nov 19, 2026 Summary
Analyst consensusStrong Buy 3Buy 9Hold 516 analysts 3-year price (USD)Factor profileMulti-factor score 47 / 100 Market data
Business descriptionPhilip Morris International is the world's largest publicly traded tobacco company, with a 29.2% share of international cigarette and heated tobacco volumes (excluding China). PM sells 607B cigarettes annually under marquee brands like Marlboro, Parliament, and Virginia Slims, while rapidly pivoting to smoke-free products — ZYN nicotine pouches and IQOS heated tobacco — which now constitute 42% of revenue and 43% of gross profit (2025). Competitive moat
Recent developments
Investment risks / red flags
Financials
Classification
|
Last updated: Aug 10, 2026
Current price: $192.73 · Nov 19, 2026· USD
CFRA Ratinghold
TBI Multi Score47
Related Peers
Loading graph…
Factor Profile (Spider Chart)
TBI ModelPrice Chart (TradingView)
Symbol: PMBusiness description
Philip Morris International is the world's largest publicly traded tobacco company, with a 29.2% share of international cigarette and heated tobacco volumes (excluding China). PM sells 607B cigarettes annually under marquee brands like Marlboro, Parliament, and Virginia Slims, while rapidly pivoting to smoke-free products — ZYN nicotine pouches and IQOS heated tobacco — which now constitute 42% of revenue and 43% of gross profit (2025).
Competitive moat
- Dominant global tobacco market share (29.2% ex-China) with iconic premium brands (Marlboro) providing exceptional pricing power and 67% gross margins among the highest in Consumer Staples.
- First-mover advantage in heated tobacco (IQOS) and nicotine pouches (ZYN), with smoke-free products growing 12.8% in volume and now 42% of revenue.
- High barriers to entry from heavy regulation, excise taxation, and litigation risk protect incumbent positions.
- Stellar earnings track record — only one quarterly miss (Q4 2023) since 2017, reflecting conservative guidance and consistent execution.
- Defensive characteristics: low beta (0.4), 3%+ dividend yield with 18 consecutive years of dividend increases, and ample free cash flow.
Recent developments
- Smoke-free momentum: Smoke-free products reached 42% of revenue in 2025; ZYN nicotine pouches and IQOS driving top-line growth, offsetting cigarette volume declines of 2.2%.
- Q1 2026 beat: Adjusted EPS of $1.96 (+16% Y/Y) ahead of consensus; revenues up 9.1% driven by pricing and smoke-free volume (+9.1%).
- Swedish Match acquisition integration: $14B deal closed in 2022 continues to drive oral product growth; ZYN Ultra launched in U.S. seen as catalyst.
- Currency tailwind: Weakening U.S. dollar providing a $0.25/share EPS benefit in 2026, up from $0.04 in 2025.
Investment risks / red flags
- CFRA is Hold with $175 target: Stock at $192.98 trades above CFRA's $175 target; risk/reward seen as balanced after significant outperformance.
- Regulatory pressure: Italy penalty for misleading "smoke-free" marketing; ongoing global regulatory scrutiny on nicotine products; potential flavor bans and marketing restrictions.
- Secular volume decline: Global cigarette consumption declining ~2% annually; developed markets declining mid-single-digit; any shift in consumer habits away from nicotine would compound headwinds.
- Currency exposure: Despite near-term tailwinds, significant non-U.S. operations create ongoing FX translation risk.
- Elevated debt: Total debt of $51.9B (116% debt/capital) following Swedish Match acquisition; share repurchase program remains suspended.
Market Data
Source: mkts.io · Nov 19, 2026, 00:00 UTC
Key Metrics
P/E (TTM)28.14
P/E (Fwd)21.31
Dividend3.29%
Beta0.35
52W High$214.35
52W Low$146.35
Analyst Consensus
3
9
5
Strong Buy3Buy9Hold516 analysts
Consensus Target$212.69
+10.4% upside
Calendar Events
Next EarningsOct 21, 2026
Ex-DividendOct 2, 2026
Dividend DateOct 26, 2026
Financials
Revenue$43.14B
Rev Growth5.50%
Earnings Growth-4.80%
Gross Margin67.70%
Op Margin41.87%
Profit Margin24.83%
EBITDA$20.12B
ROA16.88%
Rev/Share$27.70
Total Cash$6.69B
Total Debt$47.73B
Free Cash Flow$11.53B
Op Cash Flow$15.15B
Current Ratio1.02
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | 1.82 | $10.85B |
| +1q | 2.05 | $10.56B |
| 0y | 8.35 | $43.62B |
| +1y | 9.04 | $45.78B |
Earnings
Quarterly EPS
4Q2025
Est: 1.701.70Beat
1Q2026
Est: 1.831.96Beat
2Q2026
Est: 2.052.20Beat
3Q2026
Est: 2.322.36Beat
Annual
2022
Rev $31.76BEarn $9.05B
2023
Rev $35.17BEarn $7.81B
2024
Rev $37.88BEarn $7.06B
2025
Rev $40.65BEarn $11.35B
Rating Changes
| Date | Firm | Action | To |
|---|---|---|---|
| Nov 3, 2026 | Stifel | main | Buy |
| Oct 26, 2026 | Argus Research | main | Buy |
| Oct 22, 2026 | UBS | main | Neutral |
| Oct 22, 2026 | Needham | main | Buy |
| Sep 23, 2026 | UBS | main | Neutral |
| Jul 30, 2026 | Citigroup | main | Buy |
